NewsEvents

Your Yourlocation: Home > To observe the clinical effect of tiotropium bromide(136310-93-5) powder inhalation combined with sulinde inhaler in the treatment of acute exacerbation of bronchial asthma in children

To observe the clinical effect of tiotropium bromide(136310-93-5) powder inhalation combined with sulinde inhaler in the treatment of acute exacerbation of bronchial asthma in children. 

Methods: A total of 95 children with acute exacerbation of bronchial asthma who were treated in May 2012 to April 2014 were randomly divided into treatment group (n = 49) and control group (n = 46). The control group, antispasmodic and sulton inhalation therapy, the treatment group on the basis of the control group with tiotropium bromide(136310-93-5) powder inhalants, compared the two groups of children with lung function, clinical symptoms subsided time, 14 days after treatment to determine the clinical efficacy. 

Results: After 3 days of treatment, the pulmonary function, arterial blood gas index and airway inflammation index of the two groups were significantly improved compared with those before treatment. After FEV1 was (1.61 ± 0.32) L vs (1.48 ± 0.30) L, PEA was (2.39 ± 0.61) L/s vs (212 ± 0.50) L/s, PaO2 was (77.1 ± 7.6) mmHg vs (73.4 ± 7.2) mmHg, PaCO2 was (36.6 ± 4.9) mmHg vs (39.5 ± 4.5) MmHg and IL8 were (37.2 ± 9.3) μg/ml vs (44.3 ± 10.8) μg/ml, the difference was statistically significant. 

Conclusion: The combination of tiotropium bromide(136310-93-5) powder inhalation combined with sulpiride in the treatment of acute bronchial asthma in children can improve pulmonary ventilation and pulmonary ventilation function, reduce airway inflammation, no significant increase in adverse reactions, help to improve clinical efficacy.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved